Skip to main content
Top

Open Access 10-03-2025 | Esophageal Cancer | Original Article

Circulating exosome-derived miR-191-5p is a novel therapeutic biomarker for radiotherapy in esophageal squamous cell carcinoma patients

Authors: Huan Wang, Yasunori Matsumoto, Abula Maiyulan, Takeshi Toyozumi, Ryota Otsuka, Nobufumi Sekino, Koichiro Okada, Tadashi Shiraishi, Toshiki Kamata, Hisahiro Matsubara

Published in: Esophagus

Login to get access

Abstract

Background

Circulating exosomal microRNAs are an easily obtained and minimally invasive biomarker for cancer treatment. Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive carcinomas. It would thus be extremely crucial to predict therapeutic sensitivity and the patient prognosis in advance.

Methods

A search for miRNAs with a therapeutic biomarker in ESCC was performed using the miRNA expression signatures obtained from ESCC plasma exosomes before chemoradiotherapy. miR-191-5p was selected based on a comparison of miRNA signatures and the findings of previous reports. We explored the utility of circulating exosomal miR-191-5p as a prognostic biomarker of chemoradiotherapy along with its target gene, molecular pathway and functions specifically related to radiotherapy in ESCC.

Results

Overexpression of miR-191-5p promoted ESCC cell proliferation, invasion and migration. miRNA-191-5p overexpression promoted cell survival and reduced cell apoptosis after irradiation. Mechanistically, miR-191-5p may downregulate death-associated protein kinase 1 (DAPK1) to induce radiation resistance via the MAPK-JNK pathway. The 5-year progression-free survival rate for ESCC patients who underwent treatment, including radiotherapy with high circulating exosomal miR-191-5p expression was significantly lower than in those with a low expression.

Conclusion

Tumor-derived exosomal miR-191-5p is a potential non-invasive biomarker for predicting the prognosis in esophageal cancer patients after radiotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
4.
6.
go back to reference Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120:21–4.CrossRefPubMed Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120:21–4.CrossRefPubMed
7.
go back to reference Tanaka Y, Kamohara H, Kinoshita K, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013;119:1159–67.CrossRefPubMed Tanaka Y, Kamohara H, Kinoshita K, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013;119:1159–67.CrossRefPubMed
8.
go back to reference Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108:644–52.CrossRefPubMedPubMedCentral Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108:644–52.CrossRefPubMedPubMedCentral
9.
go back to reference Yagi T, Iinuma H, Hayama T, et al. Plasma exosomal microRNA-125b as a monitoring biomarker of resistance to mFOLFOX6-based chemotherapy in advanced and recurrent colorectal cancer patients. Mol Clin Oncol. 2019;11:416–24.PubMedPubMedCentral Yagi T, Iinuma H, Hayama T, et al. Plasma exosomal microRNA-125b as a monitoring biomarker of resistance to mFOLFOX6-based chemotherapy in advanced and recurrent colorectal cancer patients. Mol Clin Oncol. 2019;11:416–24.PubMedPubMedCentral
10.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRefPubMed
11.
go back to reference Huang Q, Zhang S, Zhang H, et al. Boosting the radiosensitizing and photothermal performance of Cu2- xSe nanocrystals for synergetic radiophotothermal therapy of orthotopic breast cancer. ACS Nano. 2019;13:1342–53.PubMed Huang Q, Zhang S, Zhang H, et al. Boosting the radiosensitizing and photothermal performance of Cu2- xSe nanocrystals for synergetic radiophotothermal therapy of orthotopic breast cancer. ACS Nano. 2019;13:1342–53.PubMed
12.
go back to reference Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.CrossRefPubMed Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.CrossRefPubMed
13.
go back to reference Saeki H, Sohda M, Sakai M, et al. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2020;4:490–7.CrossRefPubMedPubMedCentral Saeki H, Sohda M, Sakai M, et al. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2020;4:490–7.CrossRefPubMedPubMedCentral
14.
go back to reference Eyck BM, van Lanschot JJB, Hulshof M, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995–2004.CrossRefPubMed Eyck BM, van Lanschot JJB, Hulshof M, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995–2004.CrossRefPubMed
15.
go back to reference Stadler JC, Belloum Y, Deitert B, et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 2022;82:349–58.CrossRefPubMed Stadler JC, Belloum Y, Deitert B, et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 2022;82:349–58.CrossRefPubMed
16.
go back to reference Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32:623–42.CrossRefPubMed Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32:623–42.CrossRefPubMed
17.
go back to reference Matsumoto Y, Kano M, Murakami K, et al. Tumor-derived exosomes influence the cell cycle and cell migration of human esophageal cancer cell lines. Cancer Sci. 2020;111:4348–58.CrossRefPubMedPubMedCentral Matsumoto Y, Kano M, Murakami K, et al. Tumor-derived exosomes influence the cell cycle and cell migration of human esophageal cancer cell lines. Cancer Sci. 2020;111:4348–58.CrossRefPubMedPubMedCentral
18.
go back to reference Song J, Liu Q, Han L, et al. Hsa_circ_0009092/miR-665/NLK signaling axis suppresses colorectal cancer progression via recruiting TAMs in the tumor microenvironment. J Exp Clin Cancer Res. 2023;42:319.CrossRefPubMedPubMedCentral Song J, Liu Q, Han L, et al. Hsa_circ_0009092/miR-665/NLK signaling axis suppresses colorectal cancer progression via recruiting TAMs in the tumor microenvironment. J Exp Clin Cancer Res. 2023;42:319.CrossRefPubMedPubMedCentral
19.
go back to reference Shi H, Huang S, Qin M, et al. Exosomal circ_0088300 derived from cancer-associated fibroblasts acts as a miR-1305 sponge and promotes gastric carcinoma cell tumorigenesis. Front Cell Dev Biol. 2021;9: 676319.CrossRefPubMedPubMedCentral Shi H, Huang S, Qin M, et al. Exosomal circ_0088300 derived from cancer-associated fibroblasts acts as a miR-1305 sponge and promotes gastric carcinoma cell tumorigenesis. Front Cell Dev Biol. 2021;9: 676319.CrossRefPubMedPubMedCentral
21.
go back to reference Elbadawy M, Usui T, Yamawaki H, et al. Novel functions of death-associated protein kinases through mitogen-activated protein kinase-related signals. Int J Mol Sci. 2018;19(10):3031.CrossRefPubMedPubMedCentral Elbadawy M, Usui T, Yamawaki H, et al. Novel functions of death-associated protein kinases through mitogen-activated protein kinase-related signals. Int J Mol Sci. 2018;19(10):3031.CrossRefPubMedPubMedCentral
22.
go back to reference Bialik S, Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem. 2006;75:189–210.CrossRefPubMed Bialik S, Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem. 2006;75:189–210.CrossRefPubMed
23.
go back to reference Tian X, Xu L, Wang P. MiR-191 inhibits TNF-alpha induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1. Int J Clin Exp Pathol. 2015;8:4933–42.PubMedPubMedCentral Tian X, Xu L, Wang P. MiR-191 inhibits TNF-alpha induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1. Int J Clin Exp Pathol. 2015;8:4933–42.PubMedPubMedCentral
24.
go back to reference Eisenberg-Lerner A, Kimchi A. DAP kinase regulates JNK signaling by binding and activating protein kinase D under oxidative stress. Cell Death Differ. 2007;14:1908–15.CrossRefPubMed Eisenberg-Lerner A, Kimchi A. DAP kinase regulates JNK signaling by binding and activating protein kinase D under oxidative stress. Cell Death Differ. 2007;14:1908–15.CrossRefPubMed
25.
go back to reference Ding H, Wen W, Ding Q, et al. Diagnostic valuation of serum miR-184 and miR-191 in patients with non-small-cell Lung cancer. Cancer Control. 2020;27:1073274820964783.CrossRefPubMedPubMedCentral Ding H, Wen W, Ding Q, et al. Diagnostic valuation of serum miR-184 and miR-191 in patients with non-small-cell Lung cancer. Cancer Control. 2020;27:1073274820964783.CrossRefPubMedPubMedCentral
26.
go back to reference Bie LY, Li N, Deng WY, et al. Serum miR-191 and miR-425 as diagnostic and prognostic markers of advanced gastric cancer can predict the sensitivity of FOLFOX chemotherapy regimen. Onco Targets Ther. 2020;13:1705–15.CrossRefPubMedPubMedCentral Bie LY, Li N, Deng WY, et al. Serum miR-191 and miR-425 as diagnostic and prognostic markers of advanced gastric cancer can predict the sensitivity of FOLFOX chemotherapy regimen. Onco Targets Ther. 2020;13:1705–15.CrossRefPubMedPubMedCentral
27.
go back to reference Gao X, Xie Z, Wang Z, et al. Overexpression of miR-191 predicts poor prognosis and promotes proliferation and invasion in esophageal squamous cell carcinoma. Yonsei Med J. 2017;58:1101–10.CrossRefPubMedPubMedCentral Gao X, Xie Z, Wang Z, et al. Overexpression of miR-191 predicts poor prognosis and promotes proliferation and invasion in esophageal squamous cell carcinoma. Yonsei Med J. 2017;58:1101–10.CrossRefPubMedPubMedCentral
Metadata
Title
Circulating exosome-derived miR-191-5p is a novel therapeutic biomarker for radiotherapy in esophageal squamous cell carcinoma patients
Authors
Huan Wang
Yasunori Matsumoto
Abula Maiyulan
Takeshi Toyozumi
Ryota Otsuka
Nobufumi Sekino
Koichiro Okada
Tadashi Shiraishi
Toshiki Kamata
Hisahiro Matsubara
Publication date
10-03-2025
Publisher
Springer Nature Singapore
Published in
Esophagus
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-025-01116-9

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video